Diseño y evaluación de un programa de seguimiento farmacoterapéutico a pacientes anticoagulados en atención primaria de salud / No disponible

ABSTRACT

The inclusion of pharmacists in primary care teams in Galicia, Spain, enables the implementation anddevelopment of pharmacotherapeutic follow-up programs. The main objective of this study was to design andevaluate a pharmacotherapeutic follow-up program for anticoagulated patients. Other objectives included:1. Establishing and quantifying follow-up-related indicators.2. Recording, quantifying and classifying drug-related problems and their solution.3. Determining and classifying their causes.4. Determining the demands for information on oral anticoagulation on the part of physicians and nurses.A prospective, longitudinal study involving a single cohort was carried out at the Centro de Saúde O Rosalin Pontevedra, Spain. The 18-month study involved 63 anticoagulated patients referred to the center by theirfamily physicians to begin pharmacotherapeutic follow-up. The evaluation of the program was based onindicators related to coverage, registration, process and results. A coverage of 100% was achieved. There wasa total of 1116 patient visits (93.64% of them scheduled). The international normalized ratio determinations were within therapeutic range in 80.86% of cases. There were 327 drug-related problems; 10.7% of them were attributed to lack of compliance and 27.2% to adjustments of the doses of the oral anticoagulant. In all, 97.81% of the interventions were accepted and 95.10% of the drug-related problems were solved; 63.83% of the requests for information on anticoagulants were related to drug interactions and the remaining 36.17% tothe analytical method, indications for changes in treatment and dose adjustment, among others. The authorsconclude that the inclusion of pharmacists in primary care teams promotes the development of pharmacotherapeutic follow-up programs with good results, and that these programs are well accepted by other health care professionals (AU)